CYRX - Cryoport selected by Cellenkos to provide on-demand COVID-19 therapy shipments

Cellenkos, a privately held, clinical-stage biotechnology company has selected Cryoport (CYRX) to provide “staged, on-demand, logistics solution for COVID-19 therapy shipments for patients.”Three of its companies, Cryoport Systems, CRYOPDP, and CRYOGENE will work in concert to “provide the highest possible available level of tracking and proactive management for the therapies,” according to Cryoport.“Temperature-controlled logistics solutions are vital for our therapy's success,” noted Tara Sadeghi, vice president, Clinical Operations, Cellenkos.“…And with the flexibility provided by Cryoport Systems, CRYOGENE, and CRYOPDP, we are able to have consistent, reliable support at each stage of our therapy's journey to the patient,” she added.Last month, Cryoport announced the acquisition of F-Airgate, a Belgium-based provider of temperature-controlled supply chain solutions.

For further details see:

Cryoport selected by Cellenkos to provide on-demand COVID-19 therapy shipments